OptiNose, Inc. (NASDAQ:OPTN) Shares Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC grew its stake in shares of OptiNose, Inc. (NASDAQ:OPTN) by 142.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,688,590 shares of the company’s stock after purchasing an additional 3,338,580 shares during the quarter. OptiNose makes up about 2.4% of Stonepine Capital Management LLC’s holdings, making the stock its 13th biggest position. Stonepine Capital Management LLC’s holdings in OptiNose were worth $3,811,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of OptiNose by 3.2% during the third quarter. FMR LLC now owns 16,541,849 shares of the company’s stock worth $11,083,000 after acquiring an additional 518,610 shares during the last quarter. Great Point Partners LLC grew its position in shares of OptiNose by 56.2% during the second quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock worth $14,276,000 after acquiring an additional 4,940,779 shares during the last quarter. Nantahala Capital Management LLC grew its position in shares of OptiNose by 442.3% during the second quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock worth $14,425,000 after acquiring an additional 10,944,444 shares during the last quarter. Rosalind Advisors Inc. grew its position in shares of OptiNose by 9.8% during the third quarter. Rosalind Advisors Inc. now owns 8,287,503 shares of the company’s stock worth $5,553,000 after acquiring an additional 740,355 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of OptiNose by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock worth $6,194,000 after acquiring an additional 62,906 shares during the last quarter. Institutional investors and hedge funds own 85.60% of the company’s stock.

OptiNose Stock Up 2.9 %

NASDAQ:OPTN traded up $0.01 during midday trading on Wednesday, reaching $0.53. The stock had a trading volume of 98,945 shares, compared to its average volume of 773,250. The firm has a fifty day simple moving average of $0.67 and a two-hundred day simple moving average of $0.92. OptiNose, Inc. has a 12-month low of $0.32 and a 12-month high of $2.10. The stock has a market cap of $79.67 million, a P/E ratio of -1.83 and a beta of -0.07.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OPTN. Piper Sandler lowered their target price on shares of OptiNose from $3.00 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of OptiNose in a research report on Wednesday, November 13th.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.